Bora Pharmaceuticals: Driving commercial viability and global growth at BIO 2024

By Isabel Cameron

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Bora Pharmaceuticals BIO Commercialization Manufacturing

Ahead of Bio International, we had an conversation with Bora Pharmaceuticals to get a glimpse of what they have in store for the event.

The company's focus spans from assisting current and prospective customers in achieving commercial viability to highlighting their extensive global distribution network, and much more.

BPR: What new products or innovations is your company showcasing at BIO 2024 this year?

We’re excited to attend BIO this year to showcase how we can help our customers successfully accelerate the development of their molecule into the market. Our team of experts will be on the stand to discuss some of the challenges facing our current and future customers to help them navigate a route to become commercially viable. We can’t wait to demonstrate how Bora will be able to future-proof their path to success.

BPR: What are you hoping to achieve from the event?

Over 20,000+ international and domestic companies attend BIO every year from across the biologics industry. Attending the show is a yearly highlight as it’s always a great opportunity to network and connect with leading experts from across the biologics landscape. We utilize the opportunity to meet our global customer base and learn more about their changing needs as the sector continues to evolve. We also seek to learn and share best practices with other industry colleagues at the event.

BPR: How does your company stay ahead of industry trends and developments in the pharmaceutical sector?

Our purpose at Bora is to make our clients’ success more certain. One of the ways we do this is by staying on top of the latest trends and developments and by keeping in close communication with our customers. It’s important for us to understand what challenges they are experiencing, the changes they are seeing and how their pressures continue to evolve so we can adapt with them to address their changing needs. 

BPR: What strategies does your company employ to ensure the quality and safety of its pharmaceutical products?

We have a well-connected global distribution network of more than 100 countries around the world so staying on top of regulatory requirements is of the utmost importance at Bora. We’re proud of our quality and regulatory track record and ensure we stay up to date with industry changes across all of the territories we operate in.

BPR: Can you discuss any plans for expansion or market growth in the pipeline?

We expanded exponentially earlier this year when we acquired genetics manufacturer, Upsher Smith. This was our first facility on US soil and we plan to continue to expand our presence across North America. Our expansion has enabled us to add new technologies and dosage forms to our portfolio and we’re excited for the future as we continue to grow from our Taiwanese roots. 

BPR: What sets your company apart from competitors in the pharmaceutical industry, and what value do you offer to your customers?

Our customer-centric approach is deeply ingrained into our culture, starting from the CEO and permeating throughout the organization. We really believe in nurturing our talent to enhance their professional growth and cultivate a collaborative and innovative working environment that fosters both creativity and excellence. As a result, our employees have a long-term commitment to delivering exceptional solutions to our customers.

We are strategically located across Taiwan, Canada, and the US which offers numerous advantages to our clients. This approach allows us to create customized reliable solutions for our customers and we are committed to ensuring that everything from scaling up and speed to capabilities and technology is supported to achieve success.

Related news

Show more

Follow us